CHIME selects Branzell as new president, CEO

Editorial Staff | | Health Exec | Policy & Regulations

The College of Healthcare Information Management Executives' (CHIME) board of trustees has selected Russell P. Branzell to serve as its president and CEO.

Branzell, who is currently the CEO of Colorado Health Medical Group, a division of University of Colorado Health, will begin his new role with CHIME on April 5, 2013.

Branzell will work in concert with current President and CEO Richard A. Correll, who will become the organization’s chief operating officer.

In November 2012, the organization announced it would create a new strategic leadership role to serve as ambassador for CHIME, the CHIME Foundation and the CHIME Education Foundation, to advance its mission, improve its organizational strength and continue its policy leadership presence in Washington.

Prior to his role as CEO for Colorado Health Medical Group, Branzell was the vice president of information services and CIO for Poudre Valley Health System (PVHS) and the president and CEO of innovation enterprises (PVHS' for-profit information services entity). Before joining PVHS, Branzell was the regional deputy CIO and executive director of information services for Sisters of Mercy Health System in St. Louis, Mo.

Branzell is a past member of the CHIME board of trustees (2004-2008), past chair of CHIME StateNet, and past chair of the CHIME Education Foundation. He served as chair of the CHIME Education Committee from 2004-2008 and is currently a member of the CHIME Healthcare CIO Boot Camp faculty. He is a Certified Healthcare CIO, a fellow of CHIME and HIMSS, and board certified through the American College of Healthcare Executives. 

Editorial Staff

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.